A detailed history of Capital Research Global Investors transactions in Astrazeneca PLC stock. As of the latest transaction made, Capital Research Global Investors holds 1,390,657 shares of AZN stock, worth $108 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,390,657
Previous 1,736,665 19.92%
Holding current value
$108 Million
Previous $117 Million 19.45%
% of portfolio
0.02%
Previous 0.03%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$61.03 - $69.57 $21.1 Million - $24.1 Million
-346,008 Reduced 19.92%
1,390,657 $94.2 Million
Q4 2023

Feb 13, 2024

BUY
$61.89 - $69.28 $13.6 Million - $15.3 Million
220,514 Added 14.54%
1,736,665 $117 Million
Q3 2023

Nov 13, 2023

BUY
$64.85 - $71.7 $24.6 Million - $27.2 Million
378,722 Added 33.3%
1,516,151 $103 Million
Q2 2023

Aug 11, 2023

BUY
$69.91 - $75.81 $7.13 Million - $7.73 Million
101,975 Added 9.85%
1,137,429 $81.4 Million
Q1 2023

May 15, 2023

BUY
$63.15 - $71.6 $65.4 Million - $74.1 Million
1,035,454 New
1,035,454 $71.9 Million

Others Institutions Holding AZN

About ASTRAZENECA PLC


  • Ticker AZN
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 3,099,020,032
  • Market Cap $242B
  • Description
  • AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...
More about AZN
Track This Portfolio

Track Capital Research Global Investors Portfolio

Follow Capital Research Global Investors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Research Global Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital Research Global Investors with notifications on news.